Multidrug-resistant tuberculosis
Tuberkulosis resistan obat ganda
Article Quality & Performance Metrics
Readership in this journal
StarRanked #8 of 205 articles by views in BMC infectious diseases
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 205 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
Abstract
Background
With almost 9 million new cases each year, tuberculosis remains one of the most feared diseases on the planet. Led by the STOP-TB Partnership and WHO, recent efforts to combat the disease have made considerable progress in a number of countries. However, the emergence of mutated strains of Mycobacterium tuberculosis that are resistant to the major anti-tuberculosis drugs poses a deadly threat to control efforts. Multidrug-resistant tuberculosis (MDR-TB) has been reported in all regions of the world. More recently, extensively drug resistant-tuberculosis (XDR-TB) that is also resistant to second line drugs has emerged in a number of countries. To ensure that adequate resources are allocated to prevent the emergence and spread of drug resistance it is important to understand the scale of the problem. In this article we propose that current methods of describing the epidemiology of drug resistant tuberculosis are not adequate for this purpose and argue for the inclusion of population based statistics in global surveillance data.
Discussion
Whereas the prevalence of tuberculosis is presented as the proportion of individuals within a defined population having disease, the prevalence of drug resistant tuberculosis is usually presented as the proportion of tuberculosis cases exhibiting resistance to anti-tuberculosis drugs. Global surveillance activities have identified countries in Eastern Europe, the former Soviet Union and regions of China as having a high proportion of MDR-TB cases and international commentary has focused primarily on the urgent need to improve control in these settings. Other regions, such as sub-Saharan Africa have been observed as having a low proportion of drug resistant cases. However, if one considers the incidence of new tuberculosis cases with drug resistant disease in terms of the population then countries of sub-Saharan Africa have amongst the highest rates of transmitted MDR-TB in the world. We propose that inclusion of population based statistics in global surveillance data is necessary to better inform debate on the control of drug resistant tuberculosis.
Summary
Re-appraisal of global MDR-TB data to include population based statistics suggests that the problem of drug resistant tuberculosis in sub-Saharan Africa is more critical than previously perceived.
Abstrak
Latar Belakang
Dengan hampir 9 juta kasus baru setiap tahunnya, tuberkulosis tetap menjadi salah satu penyakit yang paling ditakuti di dunia. Dipimpin oleh Kemitraan STOP-TB dan WHO, upaya-upaya terbaru untuk memerangi penyakit ini telah mencapai kemajuan yang signifikan di sejumlah negara. Namun, kemunculan galur mutan Mycobacterium tuberculosis yang resistan terhadap obat-obat antituberkulosis utama menimbulkan ancaman mematikan bagi upaya pengendalian. Tuberkulosis resistan ganda (MDR-TB) telah dilaporkan di seluruh kawasan di dunia. Baru-baru ini, tuberkulosis resistan ekstensif (XDR-TB) yang juga resistan terhadap obat lini kedua telah muncul di sejumlah negara. Untuk memastikan alokasi sumber daya yang memadai guna mencegah kemunculan dan penyebaran resistansi obat, sangatlah penting untuk memahami skala permasalahan ini. Dalam artikel ini, kami mengemukakan bahwa metode saat ini dalam menggambarkan epidemiologi tuberkulosis resistan obat tidak memadai untuk tujuan tersebut dan berargumen mengenai perlunya pencantuman statistik berbasis populasi dalam data surveilans global.
Pembahasan
Sementara prevalensi tuberkulosis disajikan sebagai proporsi individu dalam populasi tertentu yang menderita penyakit tersebut, prevalensi tuberkulosis resistan obat biasanya disajikan sebagai proporsi kasus tuberkulosis yang menunjukkan resistansi terhadap obat antituberkulosis. Kegiatan surveilans global telah mengidentifikasi negara-negara di Eropa Timur, bekas Uni Soviet, dan wilayah Tiongkok memiliki proporsi kasus MDR-TB yang tinggi, dan ulasan internasional terutama berfokus pada kebutuhan mendesak untuk meningkatkan pengendalian di wilayah-wilayah tersebut. Kawasan lain, seperti Afrika sub-Sahara, teramati memiliki proporsi kasus resistan obat yang rendah. Namun, jika insidensi kasus tuberkulosis baru dengan penyakit resistan obat dipertimbangkan berdasarkan populasi, maka negara-negara di Afrika sub-Sahara termasuk yang memiliki tingkat penularan MDR-TB tertinggi di dunia. Kami mengusulkan bahwa pencantuman statistik berbasis populasi dalam data surveilans global diperlukan untuk memberikan landasan informasi yang lebih baik dalam perdebatan mengenai pengendalian tuberkulosis resistan obat.
Ringkasan
Penilaian ulang terhadap data MDR-TB global dengan menyertakan statistik berbasis populasi menunjukkan bahwa masalah tuberkulosis resistan obat di Afrika sub-Sahara jauh lebih kritis daripada yang diperkirakan sebelumnya.
| Reference Key |
ruth2008multidrugresistantbmc
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ruth, McNerney;M, Zager Ellen; |
| Journal | BMC infectious diseases |
| Year | 2008 |
| DOI |
DOI not found
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
ZincirX productsfrom the team behind Journament
-
PatentYazar
Patent drafts for the EPO, USPTO and TürkPatent
From inventor notes to a DOCX draft: description, claims, abstract. The machine drafts, the attorney signs.
See how it works (opens in a new tab) -
Projenator
Have a project idea? Score and plan it with AI
AI scores your idea in five dimensions and builds a phased plan. Your first project is free, no card needed.
Start your first project (opens in a new tab)
Cookies
We use strictly necessary cookies to run the site and keep you signed in. With your permission we would also use Google Analytics to see how the site is used, and Google AdSense to show ads on journal and article pages. Both stay off unless you accept, and you can change your mind at any time. How we use cookies · KVKK notice (Türkiye)
Cookie settings
Comments
No comments yet. Be the first to comment on this article.